Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01765426 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT01765426 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 67 participants.
The verdict
NCT01765426, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety, tolerability and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) \[previously DENVax\] when administered intradermally in varied dosing schedules and via different methods of administration (conventional needle/syringe versus needle-free PharmaJet® injector).
Interventions
- DRUG Placebo
- BIOLOGICAL TDV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-02-15 |
| Est. Completion | 2014-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01765426
The ClinicalTrials.gov registry entry for NCT01765426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01765426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01765426 about?
NCT01765426 is a clinical study titled "Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector". The purpose of this study is to compare the safety, tolerability and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) \[previously DENVax\] when administered intradermally in varied dosing schedules and via different methods of administration (conventional needle/syringe versus ...
What is the current status of trial NCT01765426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2013-02-15. Estimated completion is 2014-06-26.
What interventions are being tested in trial NCT01765426?
The interventions under investigation include: Placebo (DRUG), TDV (BIOLOGICAL).
Who is sponsoring clinical trial NCT01765426?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.